Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Hellmis

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
BMC Cancer|July 2, 2025
Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancerMartin Boegemann, Mostefa Bennamoun, Louis Marie Dourthe, et al.
BJU International|December 17, 2009
Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort studySchahnaz Alloussi, Gerd Mürtz, Reinhard Braun, et al.
Prostate Cancer and Prostatic Diseases|May 30, 2023
Correction to: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trialCarsten-Henning Ohlmann, Michelle Jäschke, Peter Jaehnig, et al.
Prostate Cancer and Prostatic Diseases|April 17, 2022
LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trialCarsten-Henning Ohlmann, Michelle Jäschke, Peter Jaehnig, et al.
Cancers|December 30, 2025
First-Line Treatment with Tivozanib for Metastatic Renal Cell Carcinoma in Real-World Settings Across Germany: Results of the Prospective, Non-Interventional, Post-Approval Study T-RexViktor Grünwald, Karen Rußwurm, Ralf Eckert, et al.
European Urology|September 27, 2023
Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass)Viktor Grünwald, Philipp Ivanyi, Stefanie Zschäbitz, et al.
Lancet (London, England)|October 20, 2025
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trialMaria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al.
Prostate Cancer and Prostatic Diseases|November 2, 2025
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysisEvan Y Yu, Hiroyoshi Suzuki, Christopher M Pieczonka, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2022
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinomaGuru P Sonpavde, Cora N Sternberg, Yohann Loriot, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
BMC Cancer|July 2, 2025
Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancerMartin Boegemann, Mostefa Bennamoun, Louis Marie Dourthe, et al.
BJU International|December 17, 2009
Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort studySchahnaz Alloussi, Gerd Mürtz, Reinhard Braun, et al.
Prostate Cancer and Prostatic Diseases|May 30, 2023
Correction to: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trialCarsten-Henning Ohlmann, Michelle Jäschke, Peter Jaehnig, et al.
Prostate Cancer and Prostatic Diseases|April 17, 2022
LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trialCarsten-Henning Ohlmann, Michelle Jäschke, Peter Jaehnig, et al.
Cancers|December 30, 2025
First-Line Treatment with Tivozanib for Metastatic Renal Cell Carcinoma in Real-World Settings Across Germany: Results of the Prospective, Non-Interventional, Post-Approval Study T-RexViktor Grünwald, Karen Rußwurm, Ralf Eckert, et al.
European Urology|September 27, 2023
Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass)Viktor Grünwald, Philipp Ivanyi, Stefanie Zschäbitz, et al.
Lancet (London, England)|October 20, 2025
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trialMaria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al.
Prostate Cancer and Prostatic Diseases|November 2, 2025
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysisEvan Y Yu, Hiroyoshi Suzuki, Christopher M Pieczonka, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2022
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinomaGuru P Sonpavde, Cora N Sternberg, Yohann Loriot, et al.
Pageof 2